Hing (Asafoetida) for Digestive Health

Research suggests that asafoetida has meaningful support for digestive health applications across multiple study types, including randomized controlled trials, preclinical studies, and systematic reviews, with the overall direction of evidence being consistently positive. RCTs conducted in 2018 and 2025 both found that asafoetida formulations significantly improved symptoms of functional dyspepsia such as bloating, early satiety, and postprandial fullness compared to placebo, while laboratory and animal studies provide supporting mechanistic evidence for antispasmodic effects on intestinal smooth muscle, digestive enzyme enhancement, gastroprotective properties, and anti-inflammatory activity relevant to conditions like colitis. Studies indicate that traditional uses of asafoetida as a carminative and digestive aid appear to have some pharmacological basis, though it is worth noting that a Cochrane review summary rated the evidence for asafoetida in IBS as very low certainty, pointing to the need for more rigorously designed and larger-scale human trials before firm conclusions can be drawn. Overall, the body of evidence is encouraging but still developing, and readers should weigh the stronger clinical findings against the limitations of study size, formulation variability, and the relatively small number of high-quality human trials conducted to date.